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Abstract
Background:  This retrospective study analysed the epidemiological, clinical, and therapeutic
profiles of breast cancer in males.
Methods: We report our experience at the Hospital of the University of Baskent, where 20 cases
of male breast cancer were observed and treated between 1995–2008.
Results: Median age at presentation was 66,7 ± 10,9 years. Average follow-up was 63 ± 18,5
months. The main presenting symptom was a mass in 65% of cases (13 patients). Ýnvasive ductal
carcinoma was the most frequent pathologic type (70% of cases).
Conclusion: Male breast cancer patients have an incidence of prostate cancer higher than would
be predicted in the general population. Cause of men have a higher rate of ER positivity the
responses with hormonal agents are good.
Background
Male breast cancer(MBC) is infrequent; it accounts for
0,8% of all breast cancers, less than 1% of all newly diag-
nosed male cancers, and 0,2% of male cancer deaths. The
median age at diagnosis is 68 years, 5 years older than in
women. [1-4].
The aim of this retrospective study was to present our
results and analyse the epidemiological, clinical, and ther-
apeutic profiles of this disease in 20 cases treated in our
unit between1995 and 2008.
Patients and methods
Twenty male patients with breast cancer were treated at
our University between 1995 – 2008. median age at pres-
entation was 66,7 ± 10,9 years (range 56–90 years).
Results
Ýn two cases the disease was diagnosed incidentally after
CT scan of the thorax for other conditions. In three cases,
prostate cancer was conicident, renal cell cancer was
present in one case. The disease developed after renal
transplantation in one case, Kaposi sarcoma in one case.
There was a family history of breast cancer in two cases.
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Fourteen patients (70%) had a left-sided breast cancer and
six patients (30%) had a right-sided tumour. The median
follow-up was 63 ± 18,5 months (range: 4–149 months).
Three patients developed local recurrence (Chest wall in
one patient, axillary lymph nodes in two patients).
The presenting clinical symptom was a mass in 13 of
cases. Pain was the second complaint in 4 of cases. The
tumour associated with breast ulceration in 2 of cases and
a bloody nipple discharge in one of cases (graphic 1).
Upper outer quadrant masses were present in 80% of
cases, a retroareolar mass in 10%, and inner quadrants
mass in 10%.
Bone pain was observed in one patient, related to pres-
ence of metastases. The diagnosis was confirmed by exci-
sional biopsy in 75% cases and tru-cut biopsy in 25%
cases.
The type of surgical procedure and tumors size was
showed in Figure 1 and 2.
Pathogical analysis of the specimens revaled infiltrating
ductal carcinoma (IDC) in 70% (14 cases), which one of
has mucinous carcinoma togetherness, ductal carcinoma
in situ (DCIS) in 25% (5 cases), and one case of coexistent
apocrine carcinom and micropapillary carcinoma [5].
One of the IDC was associated with primary unkown ade-
nocarcinoma. Pathological characteristics were showed in
Figure 3
Lymph node ınvolvement
Axillary lymph nodes contained metastasis in 6 of the
cases. Five of 6 cases had more than four lymph nodes
involved. One of 6 cases had nipple areola complex inva-
sion. Four of cases had positive lymph nodes with extra-
capsular extension.
Hormone receptors
Fourteen cases had 30% to 100% positive ostrogene, pro-
gestrogene receptors. Three case had only positive
ostregene receptor. In three patients examination of hor-
mone receptore was not done
Because the operations of these 3 patients was done
between 1995–1998 and at that years receptor scanning
was not been performed routinely.
Examination of c-erb-2 oncoprotein was done in 15
patients. There was not any staining with c-erb b2 except
one case who has apocrin carcinoma.
Treatment
Adjuvant radiation therapy with an average dose of 50 Gy
was given to all of the patients who had axillary lymph
node metastasis and to whom performed breast sparing
surgery. In addition, tamoxifen therapy was also given if
the hormone receptors were positive.
Only hormonal therapy was given in one case who had an
apocrine carcinoma, and had 80% positive hormone
receptor and categorized as T2N0M0.
Adjuvant radiation therapy, chemotherapy and hormonal
therapy was given in patient(T2N0M0) who had IDC and
Distribution of patients according to the operation type Figure 1
Distribution of patients according to the operation 
type. MRM: Modified radical mastectomy, Q+AND: Quad-
ranectomy + axillary node dissection, L+AND: Lumpectomy 
+ axillary node dissection, RM: Radical mastectomy.
Dsitribution of patients according to the tumour size (T) Figure 2
Dsitribution of patients according to the tumour size 
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mucinous carcinoma together and in patient who had a
chest wall invasion.
Outcome
After the first therapy protocole the patients were taken to
a 6 month follow-up. Only 2 cases, the cases with bone
and lung metastasis, were lost. Of the cases with extracap-
sullary invasion two of them and n the patient with T4
tumour (in the chest wall) showed local recurrence.
Radio- and chemotherapy were given to these cases with a
difference of excision addition to the chest wall recur-
rence. At the end of the six month, local recurrences
regressed totally. All of the alive 18 cases came to the con-
trol in the last year. The doses of agents placed in the ther-
apy protocole of immunosuppressive patients, were
reduced to minimum. None of them shows pathological
evidence belong to metastasis or local invasion.
Discussion
MBC is an uncommon disease, which presents mostly in
the latter decades of life. It represents less than 1% of all
malignancies in men and is responsible for 0,1% of male
cancer deaths [2]. It behaves similiar to female breast can-
cer in most cases [6]. In our clinic incidence ratio is 2,
9:100 which is more than literature [7].
Men have a higher rate of ER positivity, which accounts
for good responses with hormonal agents as in our study.
We used only tamoxifen in all ER positive, DCIS cases. We
used tamoxifen combined with radiotherapy in ER posi-
tive, IDC cases. The prevalence of MBC increases with age,
with a mean age of 60–65 years at presentation [8]. Risk
factors include increasing age, radiation exposure, and fac-
tors related to abnormalities in estrogen and androgen
balance, including testicular disease, infertility, obesity,
and cirrhosis. Risk factors related to a genetic predisposi-
tion include Klinefelter's syndrome, family history, and
BRCA  gene mutations, particularly BRCA2  mutations.
Gynecomastia is not a risk factor [9].
Male breast cancer patients have an incidence of prostate
cancer higher than would be predicted in the general pop-
ulation; this risk factor has implications for prostate can-
cer screening. In a recent study of Lee UJ et all, 12 of
69(17%) patients with male breast cancer also had a diag-
nosis of prostate cancer [10]. In our study 3 of 20(15%)
patients had breast cancer with prostate cancer.
Breast cancer occurred in two patients with immunosup-
pressive disorders in our series.
MBC is usually diagnosed at an advanced stage, with a
typical subareolar mass associated with axillary lymph
nodes and pain [11,12].
The male breast contains only ductal tissue, hence, most
MBCs are of the ductal type. Histologically, 90% of male
breast cancers are invasive ductal carcinomas. Approxi-
mately 80% are ER positive, 75% are PR positive, and
35% overexpress HER-2/neu. The remaining 10% are
DCIS. Given the absence of terminal lobules in the nor-
mal male breast, lobular carcinoma, both invasive and in
situ, is rarely seen [3,4].
The most common surgical treatment is modified radical
mastectomy with axillary node dissection. Adjuvant radi-
otherapy has an important role in reducing the risk of
local recurrence in large tumors, lymph node and muscle
involvement [13]. Tamoxifen is the most widely used
adjuvant therapy, because it improves survival. It may be
associated with more limited side effects in men than in
women, like decreased libido, weight gain, hot flushes,
mood alterations, depression, insomnia and deep vein
thrombosis. There is no evidence that chemotherapy
improves long term survival. Chemoterapy may be useful
in node positive and locally advanced disease. The use of
adjuvant RT has not been conclusively proven to reduce
local recurrence.
Prognostic factors in male breast cancer are the same as in
female breast cancer and include nodal involvement,
Invasive apocrine carcinoma with desmoplastic stroma (H&E, ×100) Figure 3 (see previous page)
Invasive apocrine carcinoma with desmoplastic stroma (H&E, ×100). (A1), Estrogen receptor shows strong positiv-
ity (approximately %80 of the tumor cells) (A2), Progesteron receptor reveals the same features with ER (A3), Cytoplasm 
expression of HER2/neu, no membranous stainning (A4), Diffuse stainning for gross cystic disease fluid protein (GCDFP15) 
(A5), Invasive ductal component of the invasive mucinous carcinoma at the perifery of the tumor (H & E, ×40) (B1), H & E sec-
tions (×100) (B2), Approximately the whole of the tumor cells shows estrogen receptor positivity (B3), The same stainning 
features for progesteron (B4), There is no HER2/neu expression, whereas positive control reveals membranous staining (left 
corner) (B5), Tumor cells arranged in morula-like clusters, reffered to as an ''exfoliative appearance'' (H & E, ×100) (C1), 
There is no estrogen receptor positivity, whereas positive control reveals staining (left corner) (C2), Approximately 50% of 
the tumor cells show progesteron receptor positivity (moderate staining) (C3), There is no HER2/neu expression, whereas 
positive control reveals membranous staining (left corner) (C4), There is stainning for EMA (epithelial membran antigen) at the 
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tumor size, histologic grade, and hormone receptor status.
When matched for age and stage, survival is similar to that
in women. Poor prognosis is attributed to old age, axillary
lymph node metastases(>4) and negative hormone recep-
tors [13,14].
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